January 31, 2024 02:50 PM EST
Pharma
FDA+
Law

Rul­ing in SCO­TUS mifepri­s­tone case could lead to end­less lit­i­ga­tion, in­dus­try says

Lia DeGroot

In­dus­try groups, mem­bers of Con­gress and state leg­is­la­tures are among the wave of par­ties that asked the Supreme Court on Tues­day to pre­serve the FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times